Mortality Models for Heart Failure: Should they be de Novo or Recalibrated?

08:00 EDT 13th May 2019 | BioPortfolio

Summary of "Mortality Models for Heart Failure: Should they be de Novo or Recalibrated?"

No Summary Available


Journal Details

This article was published in the following journal.

Name: Journal of cardiac failure
ISSN: 1532-8414


DeepDyve research library

PubMed Articles [17023 Associated PubMed Articles listed on BioPortfolio]

Validity of the Seattle Heart Failure Model after heart failure hospitalization.

Heart failure hospitalization is a sentinel event associated with increased mortality risk. Whether long-term heart failure risk models such as the Seattle Heart Failure Model (SHFM) accurately assess...

Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey.

Population data indicate that one in 25 persons of African ancestry has heart failure, a condition with relatively high mortality of around 50% in 5 years. Combined hydralazine and isosorbide dinitra...

Mortality from Heart Failure and Dementia in the United States: CDC WONDER 1999-2016.

Heart failure and dementia are diseases of the elderly that result in billions of dollars in annual healthcare expenditure. With the aging of the United States population, and increasing evidence of s...

National Burden of Heart Failure Events in the United States, 2006 to 2014.

Heart failure (HF)-a serious and costly condition-is increasingly prevalent. We estimated the US burden including emergency department (ED) visits, inpatient hospitalizations and associated costs, and...

The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis.

Influenza infection is associated with increased risk for mortality and hospitalization in heart failure patients. Although there are no published randomized controlled trials examining the effect of ...

Clinical Trials [9831 Associated Clinical Trials listed on BioPortfolio]

Aldosterone Blockade in Heart Failure

Heart failure causes significant morbidity and mortality and is the most rapidly increasing cardiovascular diagnosis in North America overall prevalence is estimated at 0.4% to 2.4%. Rece...

Predictive Models of Readmission in Heart Failure

This is a prospective nested case-control study. Our goals are to create predictive models to readmissions for heart failure and also to define profiles for patients who are readmitted du...

Short and Long Term Prognosis of Patients Admitted to the ED With Acute Heart Failure

Heart failure (HF) is the leading cause of hospitalization ,rehospitalization and mortality for adults over 65 years of age. This study aimed to assess mortality, and hospitalization rate...

Acute Congestive Heart Failure Urgent Care Evaluation

This prospective validation study evaluates the ability of a risk algorithm, which can simultaneously predict the risk of death at 7 days and 30 days for patients with acute heart failure ...

Iron Deficiency in Heart Failure Patients

Heart failure is a common problem with a prevalence of 1-2% in general population and a major cause of mortality,morbidity and impaired quality of life. Anemia is afrequent comorbidity in ...

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

Quick Search


DeepDyve research library

Searches Linking to this Article